trastuzumab deruxtecan
UK Researchers ID Potential Biomarker of Response to Herceptin in Overweight Breast Cancer Patients
Premium
The study, conducted at the University of Southampton, homed in on crown-like structures of immune cells on the border of body fat and tumor tissue as a biomarker for anti-HER2 drug response.
Strata Oncology Enrolling Patients in Basket Trial Exploring Biomarker-Defined Indications
The Strata PATH trial is exploring new precision oncology indications for already marketed drugs, including for four Pfizer treatments.
AstraZeneca Q1 Oncology Product Sales Increase 14 Percent Led by Tagrisso
Revenues from AstraZeneca's oncology segment in Q1 2022 totaled $3.64 billion, comprising around a third of the company's total revenues.
Jury in Enhertu Patent Infringement Case Orders Daiichi Sankyo to Pay $41.8M in Damages
Daiichi Sankyo is awaiting the USPTO's post-grant review of the patentability of Seagen's IP, covering a linker technology integral to antibody-drug conjugate therapies.
AstraZeneca, Daiichi Sankyo to Begin Regulatory Talks to Expand Enhertu Into HER2-Low Breast Cancer
The DESTINY-Breast04 trial has shown the drug benefits for HER2-low advanced breast cancer patients who are currently ineligible for HER2-targeted drugs.